Table 2.
Past-Year Prevalence of Specific Formulations of Prescribed Stimulant Medication for attention-deficit hyperactivity disorder (ADHD)a
| Prescribed Users (n = 55)b N (%) |
Non-Misusers (n = 33)b N (%) |
Misusers (n = 22)b N (%) |
Single-Agent Misusers (n = 16)c N (%) |
|
|---|---|---|---|---|
| Adderall | 19 (34.5) | 9 (27.3) | 10 (45.5) | 7 (43.8) |
| Adderall XR | 17 (30.9) | 9 (27.3) | 8 (36.4) | 4 (25.0) |
| Concerta | 13 (23.6) | 7 (21.2) | 6 (27.3) | 2 (12.5) |
| Methylphenidate | 4 (7.3) | 2 (6.1) | 2 (9.1) | 2 (12.5) |
| Ritalin | 2 (3.6) | 1 (3) | 1 (4.5) | 1 (6.2) |
| Ritalin LA | 2 (3.6) | 1 (3) | 1 (4.5) | – |
| Focalin XR | 2 (3.6) | 1 (3) | 1 (4.5) | – |
| Ritalin SR | 1 (1.8) | 0 (0) | 1 (4.5) | – |
| Metadate ER | 1 (1.8) | 0 (0) | 1 (4.5) | – |
| Methylin | 1 (1.9) | 1 (3) | 0 (0) | – |
| Daytrana | 1 (1.8) | 0 (0) | 1 (4.5) | – |
a
The following formulations were not endorsed by any of the respondents: methylphenidate extended release, Metadate CD, Methylin ER, Focalin, amphetamine/dextroamphetamine combination, dextroamphetamine, dextroamphetamine extended release, Dexedrine, Dexedrine Spansules, Dextrostat.
b
Specific formulations not mutually exclusive; percentages do not equal 100%.
c
Specific formulations are mutually exclusive; percentages equal 100%.